SCHOTT Pharma revenue and financials

1SXP · Xetra · EUR

€25.05Change from previous close: +1.42%Absolute change: +€0.35

Close · October 6, 2026

In the fiscal year ended September 2025, SCHOTT Pharma reported revenue of €986.21M (+3.04% year over year). Net income was €146.45M, a net margin of 14.9%.

Annual revenue · 2025: €986.21M
  1. €648.67M2021
  2. €821.14M2022
  3. €898.6M2023
  4. €957.09M2024
  5. €986.21M2025

Fiscal year ending in September. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+3.04%
FY to Sep 2025 vs FY to Sep 2024
Net income growth
−2.16%
FY to Sep 2025 vs FY to Sep 2024
Net margin
14.9%
FY to Sep 2024: 15.6%

Financial data

Amounts in millions of EUR; per-share values in EUR; shares in millions.

Cash flow · Quarterly
ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Operating cash flow45.691.73.452.355.247.525.175.457.925.466.041.6
Depreciation and amortization22.221.921.422.119.719.118.518.016.515.814.613.9
Capital expenditure-32.3-26.6-23.4-55.4-38.0-29.8-21.1-64.6-23.9-28.2-28.5-88.8
Investing cash flow-48.2-13.9-43.7-70.9-43.28.8-59.6-174-24.2-28.6-28.6-85.1
Financing cash flow-0.7-75.542.612.6-9.1-47.628.6101-30.00.8-39.647.5
Dividends paid0.0-27.1—0.00.0-24.1———-22.6——
Debt issued———16.6———61.9-1.00.70.3-0.3
Debt repaid-1.0-1.0-0.9-0.9-0.9-0.9-2.1-1.2-1.0-0.7-0.7-1.5
Effect of exchange rates0.40.8-0.20.1-0.70.6-0.5-1.0-0.5-0.0-0.9-0.5
Net change in cash-2.93.22.1-5.82.29.3-6.41.03.1-2.3-3.03.5
Free cash flow13.365.1-20.0-3.117.217.74.010.934.0-2.837.5-47.2
Levered free cash flow-17.073.8-54.7-21.6-28.936.8-45.1-6.840.8-93.0-12.0-36.4